Blood pressure (BP) is a heritable risk factor for cardiovascular disease. To investigate genetic associations with systolic BP (SBP), diastolic BP (DBP), mean arterial pressure (MAP), and pulse pressure (PP), we genotyped~50,000 SNPs in up to 87,736 individuals of European ancestry and combined these in a meta-analysis. We replicated findings in an independent set of 68,368 individuals of European ancestry. Our analyses identified 11 previously undescribed associations in independent loci containing 31 genes including PDE1A, HLA-DQB1, CDK6, PRKAG2, VCL, H19, NUCB2, RELA, HOXC@ complex, FBN1, and NFAT5 at the Bonferroni-corrected array-wide significance threshold (p < 6 3 10
Introduction
Blood pressure (BP) is a major, modifiable determinant of cardiovascular disease (CVD) risk. 1 Hypertension (MIM twin studies has been estimated to be approximately 50%-60% 3, 4 and~40% in family studies. Several studies have been performed to elucidate underlying genetic factors for BP, including genome-wide association studies (GWASs), meta-analyses, and admixture mapping. [5] [6] [7] [8] [9] [10] [11] [12] Efforts to dissect the genetic basis for this complex disorder have proven challenging and currently only a small portion of the total variation in BP can be explained by common genetic variants associated signals. Part of this ''missing heritability'' is likely to be due to as yet unknown common or low-frequency variants, and a fraction of it could be identified by increasing sample size. Increased understanding of the underlying genetics may contribute to improvement of the treatment to reduce CVD risk.
We conducted an association analysis of BP phenotypes in 87,736 individuals of European ancestry by using a gene-centric array with~50,000 SNPs capturing variation in~2,100 genes related to CVD, and we replicate our findings in 68,368 independent individuals. We also performed extensive bioinformatics analyses to identify regulatory regions by using the Encyclopedia of DNA Elements (ENCODE), eQTL studies, and pathway analyses. Finally, all previously reported BP-associated loci and the genes within were annotated for their suitability as drug targets.
Material and Methods

Population Characteristics
Phenotype and genotype data from 87,736 individuals of European ancestry from 36 participating studies were used for the discovery phase, and an additional 68,368 individuals of European ancestry, from 19 additional studies, were used in the replication phase. All individuals in these studies provided informed consent, and each study was approved by its own local ethics committee. Descriptions of the participating cohorts are provided in the original publications. 5, 8, 11, 13 Phenotypes Pulse pressure (PP) was defined as systolic blood pressure (SBP) minus diastolic blood pressure (DBP), and median arterial pressure (MAP) was defined as 2/3 DBP plus 1/3 SBP. Each cohort provided regression models for its respective data, adjusted for age, agesquared, body mass index (BMI), and any study-specific corrections for population substructure (based on principal components analysis). BP values were adjusted for antihypertensive drug therapy by adding a standard treatment adjustment of 15 mmHg to the SBP and 10 mmHg to the DBP values of individuals receiving treatment in the discovery and replication cohorts. These adjustments were implemented prior to the calculation of MAP and PP.
Genotyping
A total of 52,029 SNPs were included in the meta-analyses, and all SNPs were present in at least one of the three iterative versions of the Illumina HumanCVD BeadChip (also known as the ''Cardiochip'' or the ITMAT-Broad-CARe [IBC] array manufactured by Illumina) 14 used by all discovery cohorts. Several studies that used this array have already been published for a variety of phenotypes and disease outcomes, including coronary artery disease, 16, 17 During the meta-analysis step, SNPs with frequencies incompatible with HapMap CEU frequencies were removed (defined as >30% difference in the minor allele frequencies) for each data source separately, i.e., the meta-analysis results of IBC BP, of CVD-50, and of BOSS, EHLS, and BDES. We used inverse variance weighted meta-analysis in MANTEL 23 to obtain a fixed-effect estimate and statistical significance for each SNP. We applied genomic control 24 to each data set to control effects possibly resulting from population stratification or cryptic relatedness. The CARe IBC array studies, included in this meta-analysis, determined that after accounting for linkage disequilibrium (LD), the effective number of independent tests was~20,500 for Europeans. This resulted in an experimental or ''arraywide'' statistical threshold of p ¼ 2.4 3 10 À6 to maintain a false-positive rate of 5% 25 and therefore we have adopted this threshold for this study. For each associated locus, the LD patterns were examined and independence between the loci identified in this study and previously published signals was verified with SNAP 26 (r 2 < 0.3).
Replication analysis was conducted in independent samples for each trait, for SNPs with association p < 1 3 10 À5 in the discovery analysis, with a total of 68,368 individuals from the Global Blood Pressure Genetics (GBPG) consortium, 10 Women's Genome Health Study (WGHS), 27 and PREVEND 28 and LifeLines 29 studies.
We combined discovery and replication data in a meta-analysis and accounted for testing four phenotypes (albeit highly correlated), resulting in a Bonferroni-corrected threshold of p < 6 3 10 À7 for the combined meta-analysis of discovery and replication samples.
Definition of Associated Gene Variants and Variant Functional Analysis
The extended locus around each associated SNP was defined by identification of all SNPs showing r 2 R 0. 33 and nine eQTL studies. 32 Associated genes were reviewed for evidence linking them to BP-related phenotypes via PubMed and ''hypertension,'' ''cardiovascular disease,'' or ''vascular disease'' as medical subject headings (MeSH) terms. MeSH is a controlled vocabulary created by the National Library of Medicine (NLM) to index journal articles and books in the life sciences. All articles in MEDLINE have been annotated with MeSH by NLM curators or designees, offering a sensitive measure of correlation between biological traits and genes in the literature. 34 We also checked for annotation to the gene ontology term ''regulation of blood pressure,'' which also represents a highly curated set of genes consistently linked to blood pressure. 35 At a pathway level, we used GeneGo Metacore (Thomson Reuters) to construct a custom BP network based on 436 genes annotated to the ''hypertension'' MeSH term and gene ontology terms described above. The Metacore database is a large commercial database of curated human, rat, and mouse gene and protein interactions individually evidenced in the literature. 36 This allowed us to construct a core network of interacting genes that are each individually linked to blood pressure, which collectively are likely to represent a significant blood pressure gene network. We used this network as a tool to investigate direct interactions between the blood pressure gene network and the genes in the blood pressure loci reported here. By combining network data with data on gene and variant function, we were able to prioritize genes based on their level of support with respect to BP phenotypes.
Analysis of Pharmacologic Targets
We annotated genes containing variants in LD (HapMap CEU r 2 > 0.5) with discovered associations and analyzed information concerning potential druggability-that is, the potential for modulation of the protein target by a water-soluble small-molecule drug. Druggable proteins usually contain a defined binding pocket or active site, which could act as a site of action (pharmacophore) for an orally bioavailable small-molecule drug. We grouped proteins into four druggability classes, based on complementary annotations of the potentially druggable genome and publicly available databases of small molecules. Targets in class 1 are already drugged with a marketed drug recorded in DrugBank; class 2 have small molecules recorded in ChEMBL, which may include compounds in current development within pharmaceutical companies, and could be used as tools in animal and cellular models; class 3 are homologous to class 1 or class 2 targets; and class 4 are predicted to contain a potentially druggable pharmacophore based on de novo structure-based druggability prediction via the online available DoGSiteScorer tool, 37 which binds site prediction, analysis, and druggability.
Expression Quantitative Trait Loci Analysis
We identified alias identifiers for significant index SNPs by using SNAP, an online tool for LD calculations. 26 Two replication studies with more modest association were also included. We placed more value on eQTLs with low p values that showed consistent reporting across independent studies. In each case where a SNP or proxy was associated with transcript levels, we further examined the strongest eSNP for that transcript within that data set (best eSNP) and the LD between the best eSNP and BP-selected eSNPs to estimate the concordance of the BP and expression signals.
Results
Discovery Meta-analysis
In the discovery meta-analysis, four BP traits were analyzed in 87,736 individuals from 36 cohorts, as described in Table S1 available online. We analyzed SBP, DBP, MAP, and PP as continuous traits. Cohort characteristics, including age, sex, BP values, and the proportion of individuals treated with BP-lowering medications, are provided in Table S1 . Association analyses were successfully carried out for up to 48,616 SNPs that passed QC. We identified 17 SNPs that passed a suggestive discovery p value threshold of p < 1 3 10 À5 with six SNPs showing strongest associations with SBP, i.e., lowest p value among all four traits (and one secondary association, i.e., a threshold-passing p value but with a higher p value than in another trait), two SNPs showing strongest associations with DBP (and two other secondary associations), two showing strongest associations with MAP (and two other secondary ones), and three leading associations to PP (with three secondary associations).
Replication Analyses
Replication testing was performed in 68,368 additional individuals from 19 cohorts with genome-wide SNP genotypes imputed to HapMap, only to the signals passing the threshold on discovery and previously not published. A meta-analysis of the 17 SNPs taken forward from the discovery phase with replication data showed that 11 SNPs at independent loci met our Bonferroni-corrected arraywide significance threshold of p < 6 3 10 À7 . Some of these SNPs showed association with more than one trait, which resulted in 17 previously not described associations: three loci were associated with DBP (PDE1A (Figure 1 ). The association results are summarized in Table 1 . We also found a suggestive association in ERAP1 (MIM 606832) with 2.4 3 10 À6 > p > 6 3 10 À7 , which reached array-wide significance but not Bonferroni-corrected significance (array-wide significance divided by the number of traits, four). We compared the results of our analysis with all published associations at the time of this report (to the best of our knowledge) 5, [8] [9] [10] [11] 22, [74] [75] [76] [77] and confirmed previously reported BP associations at 27 loci with same direction of effect (at a nominal association threshold [p < 0.05]), out of 32 loci covered by this genotyping array, with partial sample overlap between original findings and our study (Table S2 contains all previously reported loci and our p values for these associations; each column with an X indicates a significant result was found by the referred study to the specified trait). We did not find supportive evidence of association with BP of five loci: CACNB2 (MIM 600003), CDH13 (MIM 601364), C10orf107 (MIM not available), ZNF652 (MIM 613907), and STK39 (MIM 607648), which were found in GWAS meta-analyses. The IBC array does not contain lead SNPs or proxies for 18 of the previously reported loci identified by GWASs. Table S4 presents the results in more detail.
Extended Locus Analysis and Variant Functional Analysis
Variants in LD (r 2 > 0.5) with the 11 replicated SNPs are functionally annotated in Table S5 , and a nonredundant list of corresponding genes appear in Table S6 . Several loci contained only one gene (PDE1A, HLA-DQB1, CDK6, PRKAG2, and FBN1), whereas others contained several genes (see Table S6 ). By comprehensive functional annotation, we reviewed the genes at each locus both for evidence of functional impact (genic and regulatory) and a rationale in BP.
Discussion
In this study we identified 11 loci associated with BP traits (p < 6 3 10 À7 ) in a meta-analysis comprising 87 85 and hematocrits. 86 The FBN1 locus encodes fibrillin-1 (FBN1), a component of elastic fibers in connective tissue, and this gene has been associated with Marfan syndrome (MIM 154700), with systolic and pulse pressure, with aortic stiffness in patients with coronary artery disease (CAD), 87, 88 and with thoracic aortic aneurysms and thoracic aortic dissection. 89 CDK6 variants are associated with height (MIM 606255) in a number of studies [90] [91] [92] and are implicated in white blood cell counts in Japanese populations 93, 94 and in African Americans. 95 
Associated Loci with Multiple Genes
The remaining loci (VCL, H19, NUCB2, SIPA1, HOXC4, and NFAT5) contain several genes that we have prioritized on the basis of variant functionality and the biological rationale of the genes in the BP phenotypes. We consider vinculin (VCL) the strongest biological candidate. Vinculin is a cytoskeletal protein, localized to intercalated discs, and by anchoring thin filaments it is implicated in cardiac force generation. Targeted disruption of vinculin in mice has shown loss of cardiac contractility in embryonic development. 96 The two other candidates at the VCL locus (AP3M1 and ADK) show moderate evidence of functional variation. The H19 locus contains three genes. H19 (H19, imprinted maternally expressed transcript [nonprotein coding]) expresses a noncoding RNA. Methylation defects in this gene have been associated with pre-eclampsia in a study with 188 pregnancies 97 and imprinting syndromes such as Beckwith-Wiedemann syndrome (MIM 130650) and growth retardation disorder Silver-Russell syndrome (MIM 180860). 98, 99 The locus also contains the mitochondrial ribosomal protein L23 (MRPL23) and an antisense transcript MRPL23-AS1. There are no data suggesting a putative role in BP for the latter, but eQTL analysis identified a putative isoform of MRPL23 (AK126915). The NUCB2 locus contains four genes: PIK3C2A, NUCB2, NCR3LG1, and KCNJ11. The product of NUCB2, nucleobindin 2, induces hypertension when intracerebrally administered. 100 It is also involved in the maintenance of calcium blood levels, feeding behavior, water intake, glucose homeostasis, and the release of tumor necrosis factor from vascular endothelial cells by interacting with ERAP1. 101, 102 It has been also associated with height in GWASs. [90] [91] [92] The potassium inwardly rectifying channel, encoded by KCNJ11, is also a good biological candidate, which has been reported to be associated with hypertension 103 as well as type 2 diabetes, although the previously reported variants are not in LD with the association reported in this study. The SIPA1 locus contains seven genes: MAP3K11, PCNXL3, SIPA1, RELA, KAT5, RNASEH2C, and AP5B1. SIPA1 (signal-induced proliferation-associated 1) is the strongest functional candidate, and the associated SNP encodes a nonsynonymous p.Ser182Phe polymorphism, which is predicted to be deleterious by several bioinformatics tools. 31 The strongest biological candidate is the adjacent RELA (a.k.a. NF-kB3), which forms part of the NF-kB protein complex and has been shown to modulate angiotensin II-induced hypertension in the paraventricular nucleus. 104 The HOXC4 locus contains three homeobox genes: HOXC4, HOXC5, and HOXC6. All three genes are closely related and encode transcription factors involved in morphogenesis. A recent trans-ethnic GWAS on blood pressure found a signal related to HOXCA, 105 suggesting that homeoboxes may have an association with blood pressure in more ethnicities. The NFAT5 locus also contains several candidates, including NFAT5 (Nuclear factor of activated T cells 5). NFAT5 is a transcription factor, recently shown to regulate vascular smooth muscle cell (VSMC) modulation. 106 In vivo studies in NFAT5
NFAT5 is directly involved in atherosclerotic lesion formation and identified NFAT5 as a positive regulator of atherosclerotic lesion formation. 107 A variant at this locus has also been associated with serum urate 81 and age at menarche. 108 Small-molecule activators of the adjacent NQO1 (NAD(P)H:quinone oxidoreductase) have been shown to ameliorate spontaneous hypertension in animal models via modulation of eNOS activity. 109 The Ubiquitinprotein ligase WWP2 is also a candidate, because it is known to bind and downregulate the epithelial Na(þ) channel (ENaC). Mutations in WWP2 have been shown to result in hypertension. 110 
Therapeutic Opportunities
Current antihypertensive medications do not show complete efficacy in all subjects and often require combination therapy of three or more drugs to reach a target blood pressure, and~10% of individuals show limited reduction in blood pressure on all therapeutic regimens. 111 This highlights the need for additional antihypertensive medications, both to improve efficacy of treatment and reduce the burden of side effects experienced, particularly where combination therapies are concerned. Among the associations reported in this manuscript, there is evidence of association for 15 genes that are either current drug targets or are potentially druggable based on the predicted potential of a protein to be modified by a small-molecule drug in our analyses. Two genes are targeted by currently widely applied drugs. The KCNJ11 product is targeted by several agents including the antihypertensive drug verapamil (DrugBank ID DB00661) and the glucose-lowering agent glyburide (DrugBank DB01016). NQO1 is targeted by several marketed anticoagulant drugs, including dicumarol and menadione (DrugBank DB00266 and DB00170). The protein encoded by RELA is part of the NF-kB protein complex, which is considered to be inhibited by several known drugs, including the antihypertensive olmesartan (DrugBank DB00275) 112 and the alcohol deterrent drug disulfiram (DrugBank DB00822). A known side effect of disulfiram in presence of alcohol exposure is hypotension, which gives support to a potential role of RELA in hypertension.
Nine genes with evidence of association have also previously described small-molecule modulators (mainly inhibitory or binding) based on a query of the ChEMBL database. The genes are listed with the number of tool compounds in parentheses: PDE1A (42), CDK6 (405), ADK (483), MAP3K11 (192), RELA (289), KAT5 (25), and PIK3C2A (10). The number of molecules identified may indicate the extent of drug discovery research that has been focused on each target. Many are likely to be the focus of pre-existing drug development in industry that may still be ongoing or terminated. 113 Once molecular properties of these compounds are considered to have a favorable profile, they could be investigated in animal models of hypertension; a large number of compounds have already been characterized: the ChEMBL database reports that 405 molecules show activity against CDK6. Most of these CDK6 inhibitors originate from the published GSK (Glaxosmithkline) kinase inhibitor set. 113 A review of the molecular properties of these molecules in ChEMBL shows that they have similar drug-like features and are likely to be orally bioavailable (based on Lipinski's rule of five compliance 114 ). As we described earlier, association is limited to CDK6 only, and because many of these drug-like molecules would be suitable for immediate evaluation in animal models of hypertension, this might be a worthwhile experiment, even in the absence of other strong evidence to support the role of CDK6 in BP. The 11 loci identified in the present study increase our knowledge on BP-related processes and shed light on plausible candidates at each locus and networks, via eQTL and pathway analysis. It is particularly interesting that most of the genes within the associations are suitable candidates for existing drugs or preclinical compounds. These new observations will help to improve our knowledge on BP and related mechanisms.
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